OrigiMed Co., Ltd. ("OrigiMed") announced that the company has signed ...
OrigiMed announced that the Human NTRK1/2/3 Genomic Alteration Testing...
OrigiMed, a China-based leading precision medicine company and Takeda,...
Bayer and OrigiMed (Shanghai) Co., Ltd. (referred to as "OrigiMed") to...
With fast advances in the medical industry, on May 11, 2019, the third...
OrigiMed (Shanghai) Co., Ltd., (OrigiMed) has formally announced the c...
On September 21, 2018, the CSCO precision medicine international sessi...
OrigiMed announces an agreement with Illumina in Shanghai, China. It w...
We evaluated the efficacy and safety of the anti-angiogenic tyrosine k...
Proteomic subgroups stratify patient survival and allocate specific tr...
This study was aimed to evaluate the antitumor activity, safety, and b...